Medizinisches Cannabis: Meta-Analyse sieht keine sichere Evidenz bei psychischen Erkrankungen Sydney – Medizinisches Cannabis wird zunehmend auch zur Behandlung von psychischen Erkrankungen eingesetzt. Eine Meta-Analyse in Lancet Psychiatry&nb…

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L. Lancet Psychiatry. 2019 Oct 25. pii…

Substitution of marijuana for opioids in a national survey of US adults.  Ishida JH, Wong PO, Cohen BE, Vali M, Steigerwald S, Keyhani S (2019)  PLoS ONE 14(10): e0222577. doi.org/10.1371/journal.pone.0222577 https://journals.plos.org/p…

Reduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis. Purcell C, Davis A, Moolman N, Taylor SM. Cannabis Cannabinoid Res. 2019 Sep 23;4(3):214-218. doi: 10.1089/can.2018.0020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC675723…

Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus Through Bi-Directional Control of ERK1-2 Phosphorylation Roger Hudson, Justine Renard, Christopher Norris, Walter J. Rushlow, Steven R. Lav…

Berlin. IACM 10th Conference on Cannabinoids in Medicine 31.10. – 2.11.2019 http://cannabinoidconference.org/